Kuno van der Post
OmniComm Systems, Inc.
Fort Lauderdale, FL - A full-service contract research organization, with clinical operations on three continents, has signed an agreement to use TrialMaster EDC from OmniComm Systems, Inc. (OTCQX: OMCM), a leading provider of clinical data management technology. Under the terms of the agreement, the CRO will use OmniComm’s TrialMaster for future studies, including an upcoming Phase Ib study on behalf of a sponsor based in the United Kingdom.
The CRO chose TrialMaster to complement an existing in-house EDC system and to provide additional support tools for more complex study designs. The CRO selected OmniComm because of TrialMaster’s built-in patient questionnaire capability, site experience for data collection and easy-to-use study build tools. OmniComm will provide the CRO with technology, training, study development, quality assurance and project management support.
“We are excited to have been selected as the organization’s EDC technology provider,” said Kuno van der Post, Ph.D., chief commercial officer, OmniComm Systems. “To have another key CRO in Europe choose TrialMaster because of the very modern user interface and fast study build capability is very rewarding. The CRO team also appreciated the built-in ability to deploy patient questionnaires, which will be a key component for capturing data directly from patients in the initial study.”
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry. OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, research organizations drive efficiency in clinical development, better manage risks, ensure regulatory compliance and manage their clinical operations performance. OmniComm provides comprehensive solutions for clinical research with an extensive global experience from more than 6,000 clinical trials. Please visit www.omnicomm.com for more information, and follow OmniComm on Twitter: @OmniCommSystems, on LinkedIn: @OmniComm Systems and Facebook: @OmniComm Systems, Inc.
OmniComm, TrialMaster and TrialOne are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.